Loading…

Azenta, Inc.AZTACompetitor analysis, valuation and peers

United States · USD·Health Care›Medical/Nursing Services

Provider of life sciences sample management, genomics services and biological/cold-chain storage solutions for research and biobanking.

Momentum leader 99
Mkt cap
$2.03B
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$42.7M
20-day average traded
Fwd P/E
83.2×
forward earnings
ROIC−WACC
-13.2 pp
WACC 12.2%
Hurdle
+34 pp
Req g minus delivered
Next earnings
84 days
10 Feb 2027
Close · USD$48.69
1D+6.3%
1W-0.4%
1M+36.3%
3M+33.4%
6M+162.2%
YTD+46.4%
1Y+65.8%
ATR %6.0%
Beta1.61
52w lowhigh2.7% off high

What Azenta does

Provider of life sciences sample management, genomics services and biological/cold-chain storage solutions for research and biobanking.

Charges for sequencing and gene-synthesis work in labs and for storing, shipping and tracking biological samples, often under multi-year agreements. It was Brooks Automation until it sold its semiconductor automation business to Thomas H. Lee Partners and renamed itself, leaving a pure life-sciences company.

Products and services

  • Biological sample storage (biobanking)
  • Genomics/sequencing services
  • Cold-chain sample logistics
  • Lab automation/consumables

Customers

  • Pharmaceutical/biotech companies
  • Academic research institutions
  • Biobanks

Where it sits in the supply chain

  • Life sciences tools/services
  • Sample management & genomics services
  • Biological sample storage, genomics…

What could go right

  • Biopharma outsourcing of sample management
  • Genomics/sequencing services demand growth

What could go wrong

  • Biotech funding cyclicality (research budgets)
  • Competitive genomics services pricing

Moat: narrow (switching costs, scale, installed base). Long-term sample-storage contracts and integrated logistics create high switching costs for research customers.

Headquarters: Burlington, Massachusetts · Founded: 1994

Named competitors

Azenta at a glance

Size Azenta (AZTA) is a United States Health Care company (Medical/Nursing Services) with a market value of $2.03B, the 1763rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $48.69 on 18 Nov 2026.

Performance Over six months the shares gained 162.2%, against +19.1% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 4.7% over the last twelve months (peer median +9.2%); the operating margin is -2.3% (peer median 7.5%).

Valuation It trades at 83.2× forward earnings against a peer median of 33.8× (most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 38% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +34 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 13.2 points below its cost of capital (12.2% WACC).

Backlog Backlog (remaining performance obligations) was $64.0M at 30 Jun 2026, down 16% on a year earlier — 0.1 years of trailing revenue. Backlog detail →

Short interest Short interest is 12.3% of the free float (30 Oct 2026).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

10015020025021 May 202621 Aug 202618 Nov 2026AZTA 249Peer median 120
Six months, rebased to 100: Azenta against the median of its 20 peers (local-currency closes).

Azenta financials

Reported figures in USD; fiscal year ends 2026-09-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
Revenue$622M$622M$594M$573M$665M
Revenue growth—+5%+4%-14%—
Gross profit$275M$275M$270M$255M$233M
EBITDA$42.4M$35.9M$49.9M$60.8M$3.39M
Net income-$167M-$167M-$55.8M-$165M-$14.3M
Free cash flow$27.4M$27.4M$38.3M$12.4M-$21.9M
Capital expenditure$30.1M$30.1M$33.9M$37.4M$39.4M
Total debt$51.9M$51.9M$59.9M$66.3M$72.0M

Quarterly statements and history in the cockpit →

Azenta competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%+150%0%+20%NEOALIF-BAGARWALEYE603882ADUSEMEISAVAHMD300244VIJAYAPSNLSNDAAMBEA002044WGSAGLTDOCUSPH1833AZTA6-month return →1-month return →
Up and to the right = strong over both horizons. Azenta is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%25×50×75×NEOALIF-BAGARWALEYE603882ADUSAVAHMD300244VIJAYAAMBEA002044WGSAGLUSPH1833AZTARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Azenta is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%ALIF-BAGARWALEYE603882ADUSEMEISAVAHMD300244VIJAYAAMBEA002044TDOC4544USPHAZTAGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Azenta is the large dot.

Azenta competitors and peer comparison

Head to head with its named competitors (AZTA vs TMO vs CRL vs ILMN)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Azenta AZTA$2.03B+162%+5%-2%83.2×38.0%
Thermo Fisher Scientific TMO$257B+53%+8%19%25.7×21.3%
Charles River Laboratories CRL$16.0B+114%-1%15%26.2×25.6%
Illumina ILMN$31.8B+48%+6%21%35.2×27.2%
Eurofins Scientific ERF.PA$16.4B+37%+3%12%22.1×12.9%

How Azenta compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Azenta against its 20 peers (data as of 18 Nov 2026)
MeasureAZTAPeer medianRank in peer set
1-month return+36.3%-2.8%highest of 21
6-month return+162.2%+19.1%highest of 21
Distance from 52-week high-2.7%-22.4%2nd highest of 21
Revenue growth (TTM)+4.7%+9.2%10th lowest of 21
Operating margin-2.3%7.5%6th lowest of 21
Forward P/E83.2×33.8×most expensive of 17
Growth the price implies (Req g, 7 yrs)38.0%5.4%3rd most demanding of 16
Growth delivered (Del g)+3.9%+8.5%6th lowest of 16
Hurdle (Req g minus delivered)+34.1 pp+5.7 ppmost demanding of 16
ROIC minus cost of capital-13.2 pp-3.4 pp5th lowest of 20
EV / EBITDA41.4×11.9×2nd most expensive of 13
Net debt / EBITDA-6.6×2.2×2nd least indebted of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Azenta AZTAUnited States$2.03B+162%+5%-2%83.2×38.0%+3.9%
NeoGenomics NEOUnited States$1.98B+72%+11%-6%53.5×n/an/a
AddLife ALIF-B.STSweden$2.13B+15%+2%8%39.0×21.1%+14.6%
Dr. Agarwal's Health Care AGARWALEYE.NSIndia$1.86B+20%+26%15%77.1×43.0%+26.9%
Guangzhou Kingmed Diagnostics 603882.SSChina$1.86B+5%-3%7%29.9×5.4%-6.1%
Addus HomeCare ADUSUnited States$2.25B+29%+12%11%16.2×4.0%+13.2%
Emeis EMEIS.PAFrance$1.78B-33%+4%3%n/a21.2%+8.5%
Aveanna Healthcare AVAHUnited States$2.37B+41%+17%12%12.2×7.7%+10.2%
Pediatrix Medical MDUnited States$2.41B+37%+2%12%12.4×-4.4%+2.0%
Dian Diagnostics 300244.SZChina$1.70B+1%-5%9%21.8×0.3%-1.1%
Vijaya Diagnostic Centre VIJAYA.NSIndia$1.69B+18%+24%32%63.0×40.4%+16.7%
Personalis PSNLUnited States$1.62B+88%+17%-157%n/an/an/a
Sonida Senior Living SNDAUnited States$1.59B-11%+70%-8%n/an/an/a
Ambea AMBEA.STSweden$1.59B+28%+11%9%15.2×1.1%+7.7%
Meinian Onehealth Healthcare 002044.SZChina$2.60B-27%-4%9%49.6×4.2%+5.7%
GeneDx WGSUnited States$1.56B+16%+15%-14%54.2×n/an/a
agilon health AGLUnited States$1.52B+12%+2%-2%34.1×n/an/a
Teladoc Health TDOCUnited States$1.47B+24%-2%-5%n/a-6.4%+18.3%
H.U.Group 4544.TJapan$1.44B+24%+1%3%39.9×9.7%+2.1%
U.S. Physical Therapy USPHUnited States$1.42B+53%+10%10%29.4×18.8%+13.0%
Ping An Healthcare and Technology 1833.HKHong Kong$1.36B-47%+8%3%33.5×3.5%-5.1%

Azenta backlog

Azenta reported $64.0M of remaining performance obligations at 30 Jun 2026, down 16% from a year earlier and down 1% from the previous quarter. That is 0.1 years of trailing revenue already under contract. Book-to-bill last quarter: 1.00.

Questions

Who are Azenta's main competitors?
Named competitors: Thermo Fisher Scientific (TMO), Charles River Laboratories (CRL), Illumina (ILMN), Eurofins Scientific (ERF.PA). The cockpit's measured peer set (industry) also includes NeoGenomics (NEO), AddLife (ALIF-B.ST), Dr. Agarwal's Health Care (AGARWALEYE.NS), Guangzhou Kingmed Diagnostics (603882.SS), Addus HomeCare (ADUS), Emeis (EMEIS.PA).
Is Azenta expensive compared with its peers?
On forward p/e it trades at 83.2× against a peer median of 33.8×, most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 38% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +34 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Azenta stock performed?
Over six months to 18 Nov 2026 the shares returned +162.2% against +19.1% for the median peer; over one year +65.8%.
What is Azenta's backlog?
Azenta's remaining performance obligations (contracted revenue not yet recognised) were $64.0M at 30 Jun 2026, -16% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.